medRxiv preprint doi: https://doi.org/10.1101/2023.08.23.23294474; this version posted August 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

1

# 1 COVID-19 self-testing: Countries accelerating policies ahead

<sup>2</sup> of WHO guidelines during pandemics: A Global Survey.

# 3 Authors and Affiliation

- 4 Melody Sakala<sup>1,2\*</sup>, Cheryl Johnson<sup>3\*</sup>, James Chirombo<sup>1,2</sup>, Jilian A. Sacks<sup>3</sup>, Rachel Baggaley<sup>3</sup> and
- 5 Titus Divala<sup>1</sup>.
- 6 1 Malawi Liverpool Wellcome Programme, Blantyre, Malawi
- 7 2 Kamuzu University of Health Sciences, Blantyre, Malawi
- 8 3 World Health Organisation, Geneva, Switzerland
- 9 \*Corresponding authors
- 10 Email: <u>msakala@mlw.mw</u> (MS)
- 11 Email: johnsonc@who.int (CJ)

# 12 Abstract

# 13 Introduction

The widespread use of antigen-detection rapid diagnostic tests (Ag-RDTs) has revolutionized SARS-CoV-2 (COVID-19) testing, particularly through the option of self-testing. The full extent of Ag-RDT utilization for self-testing, however, remains largely unexplored. To inform the development of WHO guidance on COVID-19 self-testing, we conducted a cross-sectional survey to gather the views and experiences of policy makers, researchers, and implementers worldwide.

#### 20 Methods

The survey was shared through professional networks via email and social media, encouraging onward sharing. We used closed and open-ended questions related to policy and program information concerning the regulation, availability, target population, indications, implementation, benefits, and challenges of COVID-19 self-testing (C19ST). We defined selftesting as tests performed and interpreted by an untrained individual, often at home. Descriptive summaries, cross-tabulations, and proportions were used to calculate outcomes at the global level and by WHO region and World Bank income classifications.

# 28 Results

Between 01 and 11 February 2022, 844 individuals from 139 countries responded to the 29 30 survey, with 45% reporting affiliation with governments and 47% operating at the national 31 level. 504 respondents from 101 countries reported policies supporting C19ST for a range of 32 use cases, including symptomatic and asymptomatic populations. More respondents from 33 low-and-middle-income countries (LMICs) than high-income countries (HICs) reported a lack of an C19ST policy (61 vs 11 countries) and low population-level reach of C19ST. Respondents 34 with C19ST experience perceived that the tests were mostly acceptable to target populations, 35 36 provided significant benefits, and highlighted several key challenges to be addressed for 37 increased success. Reported costs varied widely, ranging from specific programmes enabling 38 free access to certain users and others with high costs via the private sector.

39 Conclusion

Based on the survey responses, systems for the regulatory review, policy development and
 implementation of C19STappeared to be much more common in HIC when compared to LIC

in early 2022, though most respondents indicated self-testing was available to some extent
(101 out of 139 countries) in their country. Addressing such global inequities is critical for
ensuring access to innovative and impactful interventions in the context of a public health
emergency of international concern. The challenges and opportunities highlighted by survey
respondents could be valuable to consider as future testing strategies are being set for
outbreak-prone diseases.

# 48 Introduction

The emergence of SARS-CoV-2, the virus responsible for COVID-19, was declared a pandemic 49 50 by the World Health Organization (WHO) in January 2020 (1). Since then, COVID-19 has 51 caused social, human, and economic crises globally, leading to an accelerated drive for the 52 development of interventions, including diagnostic testing (2). In particular, the pandemic put 53 unprecedented strain on global health systems, leading to an urgent need for rapid and 54 accessible testing modalities particularly in low- and middle-income countries (LMICs). This 55 resulted in the widespread adoption of antigen-based rapid diagnostic tests (Ag-RDTs), which 56 can affordably provide same-day results, early diagnosis, and prompt referrals to onward services and care, including quarantine or treatment, to protect the most vulnerable (3). 57 58 C19ST was thought to reduce absenteeism at work, made people feel safer and increased 59 uptake and identification of new cases (3).

Despite ongoing transmission of SARS-CoV-2 globally, confirmed cases represent only a fraction of the number of infections, with access to testing being a major factor influencing case confirmation rates (4). While laboratory-based polymerase chain reaction (PCR) tests

were initially the gold standard for COVID-19 diagnostic testing, the development of (AgRDTs) provided an accurate, cost-effective and easily accessible alternative(5).

65

66 The advent of portable, easy-to-use, and stable Ag-RDTs has rapidly expanded access to 67 testing, opened the possibility of self-testing, and expanded the scope and potential of self-68 care. Self-testing has been an important intervention recommended by WHO across many 69 different disease areas, including HIV, viral hepatitis, and STIs, particularly in low- and middle-70 income countries (6,7). Self-testing has consistently been shown to increase access to and 71 uptake on testing overall and can greater uptake of both prevention and treatment services 72 (8,9). While the use of self-testing is increasingly available and well-accepted (10,11), it is 73 important to understand the experiences and views in the context of COVID-19 We conducted 74 a survey targeting policy makers, researchers, and implementers to generate a global 75 understanding of policies and experiences with SARS-CoV-2 AgRDTs for self-testing. Our 76 findings informed the development of WHO guidelines and serve as a future reference point 77 as global policies and practices continue to evolve.

# 78 METHODOLOGY

### 79 Study design

We conducted a cross-sectional study using a self-administered electronic questionnaire from
 1<sup>st</sup>-11<sup>th</sup> February 2022.

# 82 Setting and Participants

83 Our target participants were policy makers, implementers, and academics from all WHO 84 member states. The survey questionnaire was disseminated globally by the WHO to gather .

5

responses from a diverse range of participants, including through country and regional office
focal points, through social media (e.g. Facebook, twitter, LinkedIn) and professional
networks and associations. To ensure a wide distribution, we shared the survey through
professional networks via email and social media, encouraging onward sharing.

#### 89 Data collection tool

90 We developed the survey questionnaire in SurveyMonkey, which included questions relevant 91 to participants' understanding or perceptions of current policy, practice, and progress of 92 implementing COVID-19 AgRDT in their settings. The questionnaire focused on AgRDT use in 93 general, and we restricted our analysis to questions that focused on self-testing. We designed 94 questions to focus on the following areas: current availability of C19ST regulatory processes, 95 policy, and use, target population for C19ST, national coverage and willingness of the target 96 population to undertake C19ST, requirements and mechanisms for reporting C19ST results 97 according to policy or practice, mechanisms and costs for accessing C19ST kits according to 98 policy or practice, and benefits and challenges of implementing C19ST.

# 99 Key variables

We defined self-testing as tests performed and interpreted by an untrained individual, typically at home. Respondents provided their characteristics, including country of operation, affiliation, and level of involvement in the COVID-19 response. We asked respondents both closed and open-ended questions related to policy and program information concerning the regulation, availability, target population, indications, implementation, benefits, and challenges of COVID-19 self-testing. Respondents answered questions they were able to and not all respondents answered all questions. medRxiv preprint doi: https://doi.org/10.1101/2023.08.23.23294474; this version posted August 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

6

# 107 Statistical methods

108 We summarized the data using both tabular and graphical descriptive statistics. For tables, 109 we reported the number (n) of responses for each question without missing values, the size 110 of the analysis population (N) and calculated the proportions (n/N). We prepared cross-111 tabulations and produced grouped bar charts of key outcomes to show proportions stratified 112 by variables such as WHO region and country income level classification. We reported the 113 data at a global level and by WHO region and income classifications. We also performed some 114 analyses at the individual respondent level, and others by at the country level regardless of 115 the number of individuals. We conducted all data cleaning and analyses using the R language 116 for statistical computing.

#### 117 Ethics statement

This study was conducted with a strong commitment to ethical considerations. The survey, disseminated globally via online platforms, ensured voluntary participation. While no explicit informed consent was obtained, the purpose of the survey was clear to all participants. Some identifiable data was collected; however, participants' anonymity was strictly maintained during data management analysis and reporting; and no individual identities will be disclosed or compromised.

124 **RESULTS** 

### 125 Respondents' characteristics

From 1 to 11 February 2022, the survey received 844 responses from individuals in 139 countries. Table 1 describes the characteristics of the respondents, including their representation across all WHO regions and income classifications. medRxiv preprint doi: https://doi.org/10.1101/2023.08.23.23294474; this version posted August 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

7

Number of who respondents (n)	831	100%
WHO Region of Respondents' Country		
African	229	27.2%
Americas	80	9.5%
Eastern Mediterranean	64	7.6%
European	176	20.9%
South-East Asian	120	14.3%
Western Pacific	173	20.5%
World Bank Income Classification of Country		
Low income	74	9%
Lower middle income	424	51%
Upper middle income	134	16%
High income	199	24%
Level Of Involvement in the COVID-19 Response		
National level	390	47%
Regional/provincial/District level	223	27%
Community level	135	16%
Other	83	10%
Affiliation		
Academic	85	10%
Government	378	45%
NGO	167	20%
Private sector	92	11%
Other	109	13%

129

#### Table 1. Characteristics of survey respondents 130

131 Of the respondents, 45% identified as government officials, and 47% reported involvement in

132 implementing SARS-CoV-2 activities at the national level.

#### 133 Current availability of C19ST regulatory processes, policy and use

134 Table 2 outlines the availability of C19ST regulatory processes, policy, and use, as reported by

135 294 respondents from 92 countries across all regions at the time of the survey (early Feb

136 2022). medRxiv preprint doi: https://doi.org/10.1101/2023.08.23.23294474; this version posted August 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

8

	Does y	our country ha	Are SARS-CoV-2 Ag- RDTs used for self- testing in your country?					
	n	Policy in place, Supportive	Policy in place, not supportive	No policy, but Piloting	Developing policy	No policy, no pilot	Yes (n/N)	percent
All respondents	481	29%	5%	11%	17%	37%	259/481	54%
WHO Region of Respondents' Country								
African	137	15%	2%	7%	21%	55%	30/137	22%
Americas	35	34%	3%	6%	6%	51%	25/36	69%
Eastern Mediterranean	39	21%	5%	18%	13%	44%	24/38	63%
European	78	49%	8%	14%	10%	19%	67/77	87%
South-East Asian	80	31%	8%	14%	8%	40%	39/82	48%
Western Pacific	112	33%	4%	13%	30%	20%	74/114	65%
World Bank Income	Classifica	tion of Respon	dents' Count	ry				
Low income	92	12%	4%	12%	12%	60%	23/96	24%
Lower middle income	241	24%	4%	13%	25%	34%	121/247	49%
Upper middle income	57	28%	4%	9%	19%	40%	35/58	60%
High income	79	59%	5%	9%	3%	24%	72/83	87%

137

#### 138 Table 2. Reported availability of C19ST regulatory processes, policy, and use

139 Most respondents reported that their countries had a regulatory process in place for 140 reviewing and approving C19ST kits. Specifically, 32% (278) of respondents from 81 countries 141 reported that their countries had a C19ST policy in place or was actively developing one. 142 Notably, a lack of policy was reported more frequently by respondents from Low and Middle-

143 income countries (LMIC) nations (25.2%) than by those from high-income nations (10.1%).

144 Respondents from high-income countries were more likely to report that C19ST was used in

145 their country compared to those from low- and middle-income countries (88% vs 19%).

#### 146 **Target population for C19ST**

147 251 respondents from 15 countries reported targeting four specific populations for COVID-19 148 self-testing, of respondents who provided answers there was a range of different populations 149 noted as being targeted for the use of self-tests which included testing symptomatic medRxiv preprint doi: https://doi.org/10.1101/2023.08.23.23294474; this version posted August 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

9

150 individuals and then asymptomatic testing was noted in workplaces, in educational

- 151 institutions and to support attendance at gatherings.
- 152 National coverage and willingness of target population to undertake C19ST
- 153 Nationwide implementation of C19ST was reported by 148 respondents from 79 countries, of
- 154 which 34% were high-income and 65% were LMIC (13.5% Low income, 27.8% = Lower Middle,
- 155 21.5% = Upper Middle).

	рорі	What proportion of your national population do you estimate has used C19ST?				Based on your experience, how willing are the target populations to use C19ST?					
	n	<1%	1- 20%	20- 50%	>50%	n		Very willing	Willing	Somewhat willing	Not at all willing
All respondents (n = 134)	134	19%	33%	29%	19%	15	2	41%	30%	25%	3%
WHO Region of Res	sponde	nts' Co	untry								
African	15	27%	20%	33%	20%	18		44%	50%	6%	0%
Americas	9	11%	56%	11%	22%	9		44%	22%	33%	0%
Eastern Mediterranean	10	60%	10%	20%	10%	14		50%	7%	43%	0%
European	30	0%	13%	40%	47%	34		38%	38%	15%	9%
South-East Asian	29	28%	48%	17%	7%	31		35%	23%	42%	0%
Western Pacific	41	15%	41%	34%	10%	46		43%	30%	22%	4%
World Bank Incom	e Classif	fication	of Res	pondents	' Country	,					
Low income	16	50%	31%	13%	6%	17	,	29%	41%	29%	0%
Lower middle income	67	22%	43%	25%	9%	74		41%	24%	31%	4%
Upper middle income	17	6%	24%	65%	6%	19		37%	37%	26%	0%
High income	34	3%	18%	26%	53%	38		47%	34%	13%	5%

156 Table 3. Respondents' perception of national coverage and willingness of target population

157 to use self-tests

158 The majority of respondents noted that less than half the national population is estimated to 159 have used C19ST, with the highest perception of use reported by respondents from the 160 European region and in High-Income Countries. Respondents from HICs reported more 161 widespread use of C19ST than those from low- and middle-income countries (LMICs). For both 162 LMICs and HICs, 33.3% reported C19ST national coverage between 20 to 50%. In LMICs, 23.5% 163 reported a C19ST reach of less than 1%, while in HICs only 4.8% reported a less than 1% 164 coverage of C19ST. Most respondents across all regions perceived that the target populations 165 were either very willing or willing to use self-tests. Willingness to self-test was consistent 166 between high- and low-income country categories. 167 Requirements and mechanisms for reporting C19ST results according to policy and practice 168 Figure 1A and 1B presents results on requirements and mechanisms for reporting C19ST 169 results according to policy or practice. 170 Fig 1A. Requirements for reporting C19ST results 171 Fig 1B. Mechanisms for reporting results 172 Reporting of positive C19ST results was more common, but it was not required in some 173 regions. In both high- and low-income countries, mechanisms for reporting results included 174 in person, by phone, mobile application, and using a website. 175 Mechanisms and costs for accessing C19ST kits according to policy and practice 176 Figure 2A and 2B outlines the mechanisms and costs for accessing C19ST kits, as reported by 177 222 respondents. 178 Fig 2A. Distribution methods for C19ST

179 Fig 2B. Cost for accessing C19 kits

The most common distribution method for C19ST kits was through pharmacies (47.3%). Direct consumer costs for purchasing C19ST kits varied substantially across respondents and by country, but 58 respondents from 31 countries indicated that C19ST was free for some endusers. Free access to C19ST was reported more frequently in high-income countries than in low-income countries (37.1% vs 18.1%).

# 185 Perceived benefits, challenges, and areas of improvement

Respondents reported several challenges related to implementing C19ST, including 186 187 insufficient infrastructure for distribution and storage of C19ST, poor understanding of how 188 to use and interpret the tests, lack of training for personnel, and lack of awareness among the 189 public about the availability and benefits of C19ST. Respondents were also asked about 190 potential solutions to the challenges identified. Many respondents recommended increased 191 training and education on C19ST, including proper usage and interpretation of results, as well 192 as addressing issues related to distribution and storage of C19ST. Other suggestions included 193 increasing public awareness about the availability and benefits of C19ST, making C19ST more 194 affordable or providing free access, and increasing international cooperation to address the global shortage of C19ST. Other benefits of implementing C19ST that were mentioned 195 196 included increased confidence in identifying and controlling outbreaks, increased accuracy in 197 identifying cases, and potential reduction in the burden on healthcare systems.

### 198 Discussion

This cross-sectional study assessed the extent of policy and implementation of COVID-19 selftesting according to perceptions of targeted policy makers, implementers, and researchers contributing to various levels of COVID-19 response as of early 2022. Good survey

202 participation globally; supportive policy and more wide use reported in HIC compared to LIC 203 or LMIC – also differences across regions. On the other hand, there was high willingness to 204 use self-tests irrespective of income classification. Wide range of distribution approaches 205 reported with pharmacy/retail generally the most frequent; reported costs ranged widely 206 with free tests more available in HIC than in Low- and Middle-Income Countries. the reported 207 cost of accessing C19ST kits was variable, ranging from free to very costly (e.g. over USD 20). Reporting requirements and mechanisms also varied - generally increased expectation to 208 209 report positive results but a high proportion of respondents did note no known reporting 210 requirements. Supportive policy across a range of use cases was overwhelmingly reported by 211 most countries globally.

212

213 At the time of the survey there were no WHO guidelines on C19ST, our study played a role in 214 highlighting the global inequalities in access to COVID-19 interventions, with wider coverage 215 and access to C19ST reported in high-income countries compared to low- and middle-income 216 countries. An alternative explanation to the global differences in C19ST utilisation between 217 the global South and North could be lack of awareness and policy. Europe, which has the 218 highest proportion of population with access, had the highest proportion of respondents 219 reporting availability of policy. This highlights the role of a WHO guideline in increasing global 220 awareness and utilisation of interventions. The recently released global guidance on C19ST is 221 expected to support development of national policies.

222

223 While self-testing can be beneficial as it enables access without requiring action from 224 overstretched professional health workers; and can be more convenient without requiring

225 individuals to go to a health care facility. The widely reported supportive policy and use of 226 C19ST across a range of settings is likely to reflect the acceptable diagnostic performance 227 (12,13) and potential for scalability of this rapid testing technology, which are critical to the 228 COVID-19 pandemic response. COVID-19 Ag RDTs can be produced much faster, cheaper and 229 in large quantities for large scalability. Antigen tests offer the possibility of rapid, inexpensive 230 detection of SARS-COV-2 (14). Community engagement with relevant stakeholders is crucial 231 to successful COVID-19 implementation and scale up (6,15,16). Such community-led 232 approaches have been found to be highly effective when adapted for HIV self-testing (17),

and should be considered and adapted as part of future pandemic preparedness plans(18).

234

235 The study showed a wide range of target populations in both asymptomatic and symptomatic 236 individuals and in either non healthcare, education institution, and mass gatherings settings 237 using C19 ST. The wide range of target populations within and across regions demonstrates 238 wide applicability and the ease of use in place of professional testing. The versatility of C19ST 239 is critical during the COVID-19 pandemic when health systems are stretched for human 240 resource. This is especially important for low-income countries where the diagnostic testing 241 gap is widest in part secondary to financial and human resource challenges. Self-testing using 242 Ag-RDTs can be utilised for triage or identifying individuals with the highest viral load(19).

243 Willingness to self-test was consistent across region and income setting.

244

The willingness of target population is encouraging but not surprising because of the individual and community benefits of C19ST. Unlike professional testing, which may require a visit to a health facility, C19ST like most self-care interventions, allows users to know their

status within 30 minutes and without leaving their home. C19ST therefore limits contact with other people and speeds up commencement of post-test actions, including those related to protecting the health of the user, their family and their community. Moderate or severely symptomatic individuals may quickly see the need to access COVID-19 hospital care. Individuals who test negative, seamlessly resume usual activities, or decide to seek alternative clinical care if sick. Other studies support high perceived willingness to use C19 self-testing (7,20,21).

255

256 The study reported wider coverage and access use of C19 self-testing from high Income 257 countries compared to low- and middle-income countries. The striking differences in 258 coverage and access to C19ST between high- and low-income nations reflects substantial 259 global inequalities with respect to access to COVID-19 interventions. The strong correlation 260 between GDP and testing capacity was initially driven by the centralised nature and high 261 capital requirements of PCR testing. While C19ST offers the opportunity for wider access 262 based on the affordability of AgRDTs, the survey results suggest that there are still some 263 underlying barriers to full utilisation that need to be addressed in low income countries. To 264 address this gap, greater efforts are needed moving forward to ensure LMICs have access to 265 critical innovations and interventions during public health emergencies and pandemics.

266

The perceived challenges highlighted by respondents including users' inability to perform or interpret C19ST, false positive results, false negative results, people being forced to self-test, failure to report results, and failure to present for confirmatory testing must be taken into consideration when developing national C19ST strategies or policies. Other studies resonate

271 similar challenges on self-testing observed (8,15) from other disease program particularly HIV. 272 To address the main barrier to perform or accurately translate results, involving the 273 community in co-creation and dissemination of education materials would be beneficial. In 274 addition, some literature recommends inclusion of health promotion, layman's language and 275 public sensitization to increase implementation success of C19ST use (22,23) while users in 276 other studies recommended locally translated and easily accessible materials through online 277 or in person (8). As with other self-testing approaches, programmatic support including 278 engagement with health workers, community groups and those most affected are needed to 279 achieve the greatest impact. Future strategies using C19ST should consider how to adapt 280 materials from other self-testing programmes and services. This may improve both 281 acceptable and feasibility of implementation, as well as maximize limited resources.

282

Although the survey provides valuable insights into COVID-19 policies and practices, it is 283 284 essential to consider its limitations. The survey does not necessarily reflect the official 285 positions of countries and ministries of health but rather presents the perspectives of a 286 diverse group of respondents involved in COVID-19 work across countries. Additionally, the 287 findings represent a snapshot of policy and practice as of February 2022 and may not reflect earlier or later circumstances as the pandemic and response continue to evolve. Nevertheless, 288 289 these findings importantly highlight the views and experiences with C19ST from many 290 countries experiencing outbreaks and reporting high case rates. Thus, the findings may be 291 applicable for future planning in the event of outbreaks or seasonal spread.

The use of Ag-RDTs for self-testing is a promising solution, but our finding of limited access in low-and-middle-income countries compared to high-income countries highlights the harsh reality of global inequalities and the need to address them sustainably. Experiences shared by respondents highlighted benefits and challenges and opportunities that can inform development of effective policies to support self-testing at national and global levels. Moving forward as part of pandemic preparedness, global stakeholders need to prioritize investment to enable LMICs to benefit from critical innovations and interventions.

# 300 Acknowledgements

301 We would like to thank all participants of the survey and everyone who supported the 302 distribution. We acknowledge WHO guideline development group and colleagues for their 303 untiring feedback throughout the whole process.

304

# 305 Reference

- 306 1. WHO Director-General's opening remarks at the media briefing on COVID-19
- 307 [Internet]. 2020. Available from: https://www.who.int/director-
- 308 general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-
- 309 briefing-on-covid-19---11-march-2020
- 310 2. Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Kirley PD, et al. Risk Factors
- 311 for Coronavirus Disease 2019 (COVID-19)–Associated Hospitalization: COVID-19–
- 312 Associated Hospitalization Surveillance Network and Behavioral Risk Factor
- 313 Surveillance System. Clin Infect Dis [Internet]. 2021 Aug 4;72(11):e695–703. Available
- 314 from: https://academic.oup.com/cid/article/72/11/e695/5908300

- 315 3. Brümmer LE, Erdmann C, Tolle H, McGrath S, Olaru ID, Katzenschlager S, et al. The
- 316 clinical utility and epidemiological impact of self-testing for SARS-CoV-2 using antigen
- 317 detecting diagnostics: a systematic review and meta-analysis. medRxiv [Internet].
- 318 2022;2022.07.03.22277183. Available from:
- 319 http://medrxiv.org/content/early/2022/07/05/2022.07.03.22277183.abstract
- 320 4. Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global
- 321 seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis.
- 322 Khudyakov YE, editor. PLoS One [Internet]. 2021 Jun 8;16(6):e0252617. Available
- 323 from: https://dx.plos.org/10.1371/journal.pone.0252617
- 324 5. Organization WH. Diagnostic testing for SARS-CoV-2: interim guidance [Internet].
- 325 2020. Available from: https://apps.who.int/iris/handle/10665/334254
- 326 6. WHO. Recommendations and guidance on hepatitis C virus self-testing. 2021. 20 p.
- 327 7. WHO. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-
- 328 testing. Interim Guid. 2022;(9 March):1–16.
- 329 8. Jamil MS, Eshun-Wilson I, Witzel TC, Siegfried N, Figueroa C, Chitembo L, et al.
- 330 Examining the effects of HIV self-testing compared to standard HIV testing services in
- 331 the general population: A systematic review and meta-analysis. EClinicalMedicine
- 332 [Internet]. 2021;38:100991. Available from:
- 333 https://doi.org/10.1016/j.eclinm.2021.100991
- 334 9. Organization WH. WHO implementation tool for pre-exposure prophylaxis (PrEP) of
- 335 HIV infection: module 10: testing providers [Internet]. Geneva: World Health
- 336 Organization; 2017 Aug. Available from:
- 337 https://apps.who.int/iris/handle/10665/258516

- 338 10. Fonner VA, Luhmann N, Siegfried N, Johnson C, Baggaley R, Ford N, et al. Use of
- 339 indirect evidence from HIV self-testing to inform the WHO hepatitis C self-testing
- 340 recommendation. BMJ Glob Heal. 2023;8(2):2022–4.
- 341 11. Kiptinness C, Kuo AP, Reedy AM, Johnson CC, Ngure K, Wagner AD, et al. Examining
- 342 the Use of HIV Self-Testing to Support PrEP Delivery: a Systematic Literature Review.
- 343 Curr HIV/AIDS Rep [Internet]. 2022;19(5):394–408. Available from:
- 344 https://doi.org/10.1007/s11904-022-00617-x
- 345 12. Zwart VF, van der Moeren N, Stohr JJJM, Feltkamp MCW, Bentvelsen RG, Diederen
- 346 BMW, et al. Performance of Various Lateral Flow SARS-CoV-2 Antigen Self Testing
- 347 Methods in Healthcare Workers: a Multicenter Study [Internet]. Infectious Diseases
- 348 (except HIV/AIDS); 2022 Jun. Available from:
- 349 http://medrxiv.org/lookup/doi/10.1101/2022.01.28.22269783
- 350 13. Stohr JJJM, Zwart VF, Goderski G, Meijer A, Nagel-Imming CRS, Kluytmans-van den
- 351 Bergh MFQ, et al. Self-testing for the detection of SARS-CoV-2 infection with rapid
- 352 antigen tests [Internet]. Public and Global Health; 2021 Jun. Available from:
- 353 http://medrxiv.org/lookup/doi/10.1101/2021.02.21.21252153
- 14. Peeling RW, Olliaro PL, Boeras DI, Fongwen N. Scaling up COVID-19 rapid antigen
- 355 tests: promises and challenges. Lancet Infect Dis [Internet]. 2021 Jun 8;21(9):e290–5.
- 356 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309921000487
- 357 15. Nwaozuru U, Obiezu-Umeh C, Diallo H, Graham D, Whembolua G-L, Bourgeau MJ, et
- al. Perceptions of COVID-19 Self-Testing and Recommendations for Implementation
- 359 and Scale up Among Black/African Americans: Implications for the COVID-19 STEP
- 360 Project [Internet]. In Review; 2022 Jun. Available from:

- 361 https://www.researchsquare.com/article/rs-1277219/v1
- 362 16. Figueroa C, Johnson C, Verster A, Baggaley R. Attitudes and Acceptability on HIV Self-
- 363 testing Among Key Populations: A Literature Review. AIDS Behav [Internet]. 2015 Aug
- 364 4;19(11):1949–65. Available from: http://link.springer.com/10.1007/s10461-015-
- 365 1097-8
- 366 17. Sibanda EL, Neuman M, Tumushime M, Mangenah C, Hatzold K, Watadzaushe C, et al.
- 367 Community-based HIV self-testing: a cluster-randomised trial of supply-side financial
- 368 incentives and time-trend analysis of linkage to antiretroviral therapy in Zimbabwe.
- 369 BMJ Glob Heal [Internet]. 2021 Aug 4;6(Suppl 4):e003866. Available from:
- 370 https://gh.bmj.com/lookup/doi/10.1136/bmjgh-2020-003866
- 18. Seale H, Harris-Roxas B, Heywood A, Abdi I, Mahimbo A, Chauhan A, et al. Speaking
- 372 COVID-19: supporting COVID-19 communication and engagement efforts with people
- 373 from culturally and linguistically diverse communities. BMC Public Health [Internet].
- 374 2022 Jun 18;22(1):1257. Available from:
- 375 https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-022-13680-1
- 376 19. Porte L, Legarraga P, Iruretagoyena M, Vollrath V, Pizarro G, Munita J, et al.
- 377 Evaluation of two fluorescence immunoassays for the rapid detection of SARS-CoV-2
- 378 antigen—new tool to detect infective COVID-19 patients. PeerJ [Internet]. 2021 Jun
- 379 9;9:e10801. Available from: https://peerj.com/articles/10801
- 380 20. Hall EW, Luisi N, Zlotorzynska M, Wilde G, Sullivan P, Sanchez T, et al. Willingness to
- 381 Use Home Collection Methods to Provide Specimens for SARS-CoV-2/COVID-19
- 382 Research: Survey Study. J Med Internet Res [Internet]. 2020 Aug 4;22(9):e19471.
- 383 Available from: https://www.jmir.org/2020/9/e19471

- 384 21. Goggolidou P, Hodges-Mameletzis I, Purewal S, Karakoula A, Warr T. Self-Testing as
- an Invaluable Tool in Fighting the COVID-19 Pandemic. J Prim Care Community Health
- 386 [Internet]. 2021 Jun 8;12:215013272110477. Available from:
- 387 http://journals.sagepub.com/doi/10.1177/21501327211047782
- 388 22. Van den Broucke S. Why health promotion matters to the COVID-19 pandemic, and
- vice versa. Health Promot Int [Internet]. 2020 Aug 4;35(2):181–6. Available from:
- 390 https://academic.oup.com/heapro/article/35/2/181/5820891
- 391 23. Coste AT, Egli A, Greub G. Self-testing for SARS-CoV-2: Importance of lay
- 392 communication. Swiss Med Wkly. 2021;151(21–22):2–5.




Fig 1A




Fig 1B




Fig 2A

< 1\$	Malawi	Indonesia						
1-2\$	South Korea	Malaysia	Pakistan					
2-5\$	Portugal	Vietnam	Germany					
	India	Netherlands	Thailand					
	Singapore	Belgium						
5-10\$	Canada	Spain	Cyprus					
	Mauritius	Qatar	Finland					
	Peru	Bahrain						
10-20\$	Australia	Mexico	Ukraine					
20\$+	Russia	USA	Papua New Guinea					
	Philippines							
Fig 2B								
118 20								
0								